Wed, Jan 28, 2015, 9:56 AM EST - U.S. Markets close in 6 hrs 4 mins


% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • pharmaherooc pharmaherooc Sep 30, 2011 1:02 PM Flag

    IGXT (Mcap 28 M) // Approval date 13 Nov 2011=5 BAGGER

    PDUFA date 13 November 2011 .Partnerdeal for CPI-300 before Approval !!!

    IGXT has 3.7 M in Cash enuff till 2013 excluding revenue from CPI-300 and upfront payment from new Partnerdeal which is imminent .


    Intelgenx (IGXT.OB)

    Market Cap : 28 M$
    Cash: 3.7 M$
    Price : 0,59 $

    Shares Out : 45 M ( 20 M shares are held by Insiders + Institutions)

    IntelGenx Announces New PDUFA Date for Its Single Dose 450 mg Bupropion Hydrochloride Tablet

    Press Release Source: IntelGenx Corp. On Tuesday June 14, 2011, 6:00 am EDT

    IntelGenx Corp announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's resubmission of its antidepressant CPI-300 New Drug Application 505(b)(2) in response to the February 2010 Complete Response Letter ("CRL") as a complete, Class 2 response. In addition, the FDA has established November 13, 2011 as its target action date under the Prescription Drug User Fee Act ("PDUFA"). CPI-300 is a novel, high strength of Bupropion Hydrochloride (HCl), the active ingredient in Wellbutrin XL®.

    Upcoming Milestones

    Q3, 2011 Complete licensing agreement for CPI-300

    Q3, 2011 Execute definitive agreement for new development and licensing VersaFilm project

    Q3, 2011 Execute definitive agreement for bipolar disorder

    Q4, 2011 Obtain FDA approval for CPI-300

    Q4, 2011 Complete pivotal biostudy for anti-migraine VersaFilm


13.63-0.0500(-0.37%)Sep 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.